MedTrace Logo

Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer

NCT02117440 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2019-02-25

No results posted yet for this study

Summary

This study is designed to apply various scans such as functional imaging, Fluorodeoxyglucose\_Positron Emission Tomography (FDG-PET), 62Cu-ETS (Copper) PET, Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT), cardiac magnetic resonance imaging (MRI), Tc-99m HMPAO SPECT/CT, and pulmonary function tests before, during and after treatment to see if it predicts how well the treatment works for your cancer and how well your lungs function during treatment. A Computerized Tomography (CT) will also be performed along with both of these procedures to help the researchers see clearly where your cancer or your healthy lung is located. The researchers also perform blood tests in this study to look for markers in your blood to see if it helps them determine your risk of developing side effects from radiation to the lungs. They will also measure your health-related quality of life before, during and after treatment. The researchers hope that this study will help them in the future to design radiation treatment plans that provide the best treatment for each individual patient.

Conditions

  • Lung Neoplasms

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Feng-Ming Kong, MD · Indiana University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-03-02
Completion
2018-03-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117440 on ClinicalTrials.gov